search icon
  • Print
  • ShareThis
  • Text Size
  • View All Letters on US Resistance Efforts

  • Search More Letters

    IDSA Introduction to FDA Commissioner Gottlieb (PDF)

    IDSA wrote an introductory letter to recently confirmed US Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb offering its support and highlighting the need for new antibiotic research and development and infectious disease diagnostics.

    IDSA Leads Letter to HHS Secretary on AMR (PDF)

    IDSA led a group of over forty organizations representing health care providers, patients, public health, and industry to thank HHS Secretary Tom Price for his upcoming participation in the World Health Assembly, and to continue domestic and international work to advance a robust response to antimicrobial resistance (AMR) that reflects the US commitment to infection prevention, antimicrobial stewardship, surveillance, and innovation.

    IDSA Highlights Pressing ID Policy Issues for New HHS Secretary (PDF)

    IDSA outlines a number of pressing ID policy priorities for new HHS Secretary Dr. Tom Price, including antimicrobial resistance, domestic and global public health programs, infrastructure, and preparedness, biomedical research and innovation, and ID physician workforce issues.

    IDSA Outlines ID Policy Issues for Trump Transition Team (PDF)

    IDSA outlines important ID policy issues for Vice President-elect Mike Pence, head of the Trump Transition Team.

    IDSA Comments to PACCARB on Antibiotic Resistance Data Collection (PDF)

    IDSA comments to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria on challenges faced in gathering and sharing antibiotic resistance data.

    IDSA Applauds FDA and NIH for Advancing Federal Dialogue on Antibiotic Resistance (PDF)

    In a letter to U.S. Food and Drug Administration (FDA) commissioner Margaret Hamburg and National Institutes of Health (NIH) director Francis Collins, IDSA thanks the respective agencies for holding a productive and thought provoking public workshop on antimicrobial product development and enthusiastically welcomes NIH’s announcement of a forthcoming public-private partnership (PPP) to address antibiotic development and related effort to establish a master clinical trials protocol. IDSA has long advocated for a high-level PPP with representation from the federal government, academia, industry, physicians and other key stakeholders, to promote innovation and improvement in the discovery, development, and evaluation of new antibiotics and diagnostics.

    IDSA Calls on President Obama to Fulfill SOTU Pledge on Antibiotic Resistance (PDF)

    IDSA applauds President Obama for highlighting the need to address resistance during his State of the Union address and urges him to take specific actions, including incentivizing development of new antibiotics and diagnostics, strengthening stewardship, improving surveillance, and investing in research.

    IDSA Joins Members of Congress in Call for a Hearing on Antimicrobial Resistance (PDF)

    IDSA supports a request from Representatives Waxman, DeGette, Pallone, and Dingell to the House Energy & Commerce Committee that a hearing be held on federal efforts to address antimicrobial resistance.  Both the IDSA letter and the congressional request reference the September 2013 CDC report, Antimicrobial Resistance Threats in the United States, 2013 as evidence of the need for action.

    IDSA Urges the Obama Administration to Support Proposals Targeting Antimicrobial Resistance (PDF)

    IDSA sent a letter to President Obama seeking support for proposals addressing antimicrobial resistance that are currently being considered in Congress.  The proposals include the Limited Population Antibacterial Drug (LPAD) Pathway, R&D Tax Credits for Antibiotic/Antifungal Drugs and Diagnostics, Strategies to Address Antimicrobial Resistance (STAAR) Act, and federal funding.

    IDSA Letter to HHS on Antimicrobial Resistance and Immunization Policies (PDF)

    IDSA urges Secretary Sebelius to act on Senate recommendations regarding antimicrobial resistance, antibiotic research and development, and immunization policies.

    IDSA Comments on Draft Antimicrobial Resistance Action Plan (PDF)

    IDSA opined on the draft revised federal Action Plan to Combat Antimicrobial Resistance published by the federal Interagency Task Force in March 2011. IDSA highlighted the need for greater leadership, coordination, non-government expert input, accountable measures, and resources.

    IDSA Letter to NIAID on Clinical Trials Network and Repository

    IDSA letter supporting the new NIAID clinical trials network primarily focused on bacterial antibiotic resistance.  IDSA also proposed the establishment of an ID clinical specimen repository, which could be housed at NIAID and linked to clinical trials conducted through the network and other sites.

    IDSA Letter to President Obama raising concerns about the Federal Approach to Resistance (PDF)

    IDSA asks the White House to act to strengthen leadership and coordination of federal efforts.

    IDSA Suggests Changes to NIAID Clinical Trials Infrastructure

    In a letter to NIAID Director Fauci, IDSA provided its input on the future structure and objectives of NIAID's clinical trials infrastructure.

    IDSA Urges Action by Trans-Atlantic Task Force on Antimicrobial Resistance (PDF)

    IDSA applauds the first meeting of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR), but urges Task Force members to take swift action on the issue of antimicrobial resistance through collaboration and adoption of global efforts to combat resistance, such as the 10x'20 initiative.

    IDSA Urges NIAID Clinical Trial Networks Expansion into New Areas (PDF)

    NIAID officials are examining the possibility of expanding the Institute’s clinical trials networks to cover tuberculosis, hepatitis C, influenza research.   IDSA supports this proposal and has requested that resistant bacterial infections also be considered.

    IDSA Letter to NIAID and CDC Requesting a Strengthened Federal Response to Antimicrobial Resistance (PDF)

    In a letter to Dr. Anthony Fauci, NIAID, and Julie Gerberding, CDC, IDSA called for the creation of an NIH/CDC joint antimicrobial resistance strategic research plan as well as the joint establishment of an Antimicrobial Resistance Clinical Research and Public Health Network as proposed in the Strategies to Address Antimicrobial Resistance Act.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site